228850 — Rayence Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeMicro CapContrarian

Market Cap
KR₩88bn
Enterprise Value
-KR₩57bn
Revenue
KR₩126bn

Annual income statement for Rayence Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	101,524	134,568	147,161	142,986	125,564
Cost of Revenue
Gross Profit	36,824	55,034	62,556	57,894	48,169
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	99,914	116,469	125,132	123,641	118,932
Operating Profit	1,610	18,099	22,028	19,345	6,631
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-2,018	20,317	25,261	23,525	12,200
Provision for Income Taxes
Net Income After Taxes	-4,077	14,093	21,849	19,462	7,749
Minority Interest
Net Income Before Extraordinary Items
Net Income	-1,916	14,458	22,049	19,600	7,830
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-1,916	14,458	22,049	19,600	7,830
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	160	1,186	1,449	1,227	495
Dividends per Share